SiSaf Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $17.9M

  • Investors
  • 11

SiSaf General Information

Description

Developer of a biomaterial-based drug delivery platform designed to improve the delivery of RNA therapeutics and other therapeutic molecules. The company offers a bioabsorbable silicon matrix combined with lipids and amino acids to enhance stability, solubility, targeting, transfection efficiency, and controlled release, enabling biotechnology and pharmaceutical companies to develop therapies across diverse disease indications.

Contact Information

Website
www.sisaf.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6-8 Frederick Sanger Road
  • Guildford GU2 7YD
  • England, United Kingdom
+44 01483
Primary Industry
Drug Discovery
Corporate Office
  • 6-8 Frederick Sanger Road
  • Guildford GU2 7YD
  • England, United Kingdom
+44 01483

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SiSaf Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series B) 04-Apr-2023 $17.9M Completed Generating Revenue
11. Grant 01-Jan-2021 Completed Generating Revenue
10. Later Stage VC (Series A3) 31-Jul-2019 Completed Generating Revenue
9. Later Stage VC 01-Aug-2018 Completed Generating Revenue
8. Later Stage VC (Series A2) 31-May-2018 Completed Generating Revenue
7. Later Stage VC (Series A1) 01-Aug-2017 Completed Generating Revenue
6. Grant 01-Oct-2016 Completed Generating Revenue
5. Grant 01-Jan-2016 Completed Generating Revenue
4. Later Stage VC 18-Oct-2013 $676K $872K Completed Generating Revenue
3. Angel (individual) 11-Mar-2011 $60.5K $196K Completed Generating Revenue
To view SiSaf’s complete valuation and funding history, request access »

SiSaf Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3
Series A3
Series A3
Series A2
Series A1
Series A2
Series A2
Series A1
Series A1 359,625 $0.000122 $3.55 $3.55 1x $3.55 7.15%
Series A1 119,875 $0.000122 $3.51 $3.51 1x $3.51 2.38%
To view SiSaf’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SiSaf Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biomaterial-based drug delivery platform designed to improve the delivery of RNA therapeutics and other t
Drug Discovery
Guildford, United Kingdom
18 As of 2025

Vancouver, Canada
 

Bedford, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SiSaf Competitors (4)

One of SiSaf’s 4 competitors is Acuitas Therapeutics, a Corporation company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acuitas Therapeutics Corporation Vancouver, Canada
Stoke Therapeutics Formerly VC-backed Bedford, MA
Avanti Research Corporate Backed or Acquired Alabaster, AL
Avenir Wellness Solutions Formerly VC-backed Oxnard, CA
To view SiSaf’s complete competitors history, request access »

SiSaf Patents

SiSaf Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202511471-D0 Exosome-based compositions Pending 15-Jul-2025
GB-202511472-D0 Opthalmic delivery of exosome compositions Pending 15-Jul-2025
GB-202402999-D0 Medicinal products and uses thereof Inactive 01-Mar-2024
WO-2025181500-A1 Mirna composition accumulating in pancreas and/or spleen Pending 01-Mar-2024
GB-202300914-D0 Manufacturing process Inactive 20-Jan-2023 A61K9/1271
To view SiSaf’s complete patent history, request access »

SiSaf Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SiSaf Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Future Fund (UK) Lender/Debt Provider Minority
Croda International Corporation Minority
Vickers Venture Partners Corporate Venture Capital Minority
Innovate UK Government
Clarendon Fund Managers Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

SiSaf FAQs

  • When was SiSaf founded?

    SiSaf was founded in 2006.

  • Where is SiSaf headquartered?

    SiSaf is headquartered in Guildford, United Kingdom.

  • What is the size of SiSaf?

    SiSaf has 18 total employees.

  • What industry is SiSaf in?

    SiSaf’s primary industry is Drug Discovery.

  • Is SiSaf a private or public company?

    SiSaf is a Private company.

  • What is the current valuation of SiSaf?

    The current valuation of SiSaf is .

  • What is SiSaf’s current revenue?

    The current revenue for SiSaf is .

  • How much funding has SiSaf raised over time?

    SiSaf has raised $43.3M.

  • Who are SiSaf’s investors?

    Future Fund (UK), Croda International, Vickers Venture Partners, Innovate UK, and Clarendon Fund Managers are 5 of 11 investors who have invested in SiSaf.

  • Who are SiSaf’s competitors?

    Acuitas Therapeutics, Stoke Therapeutics, Avanti Research, and Avenir Wellness Solutions are competitors of SiSaf.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process